OTDC 2027 explores emerging advances in oligonucleotide therapeutics, RNA & mRNA, innovative delivery technologies, and research collaboration—connecting ideas that can move the field forward.
📅 May 11–12, 2027 | 📍 Boston, MA
🔗 oligo-nucleotide.com
OTDC 2027 explores emerging advances in oligonucleotide therapeutics, RNA & mRNA, innovative delivery technologies, and research collaboration—connecting ideas that can move the field forward.
📅 May 11–12, 2027 | 📍 Boston, MA
🔗 oligo-nucleotide.com
New data include CBASS recognition of diverse proteases beyond T4, and verifying CD-NTase activation loop cleavage as the trigger for defense in vivo
www.science.org/doi/10.1126/...
New data include CBASS recognition of diverse proteases beyond T4, and verifying CD-NTase activation loop cleavage as the trigger for defense in vivo
www.science.org/doi/10.1126/...
OTDC 2027 brings together emerging advances in oligonucleotide therapeutics, RNA & mRNA, and innovative delivery technologies shaping the future of medicine.
📅 May 11–12, 2027 | 📍 Boston, MA & Virtual
🔗 oligo-nucleotide.com
#OTDC2027
OTDC 2027 brings together emerging advances in oligonucleotide therapeutics, RNA & mRNA, and innovative delivery technologies shaping the future of medicine.
📅 May 11–12, 2027 | 📍 Boston, MA & Virtual
🔗 oligo-nucleotide.com
#OTDC2027
Maxwell Z. Wilson & Siddharth S. Dey in Nat Biotech
#Epigenetics #SingleCell #Multiomics
---
epigenometech.com
Maxwell Z. Wilson & Siddharth S. Dey in Nat Biotech
#Epigenetics #SingleCell #Multiomics
---
epigenometech.com
🔹DMD | PMO exon skipping; PPMOs & AOCs aim to improve muscle delivery
🔹DM1 | ASOs & AOCs target DMPK RNA
🔹OPMD | Gene therapy approaches are under exploration
🔹LGMD | Gene therapy & oligonucleotide approaches are being investigated for selected subtypes
🔹DMD | PMO exon skipping; PPMOs & AOCs aim to improve muscle delivery
🔹DM1 | ASOs & AOCs target DMPK RNA
🔹OPMD | Gene therapy approaches are under exploration
🔹LGMD | Gene therapy & oligonucleotide approaches are being investigated for selected subtypes
A new #LabMedDiscovery review explores antibody–oligonucleotide conjugates (AOCs)—
🔬 One platform, bridging diagnostics and therapeutics
www.sciencedirect.com/science/arti...
#AOC #LaboratoryMedicine #MultiOmics #RNA #Diagnostics
A new #LabMedDiscovery review explores antibody–oligonucleotide conjugates (AOCs)—
🔬 One platform, bridging diagnostics and therapeutics
www.sciencedirect.com/science/arti...
#AOC #LaboratoryMedicine #MultiOmics #RNA #Diagnostics
Register for OTDC 2027 and connect with advances in Oligonucleotide Therapeutics, RNA Technologies, Drug Delivery, CRISPR & Aptamer Technologies.
📅 May 11–12, 2027 | Boston + Hybrid
🔗 oligo-nucleotide.com
#OTDC2027 #Oligonucleotides #RNATherapeutics #DrugDelivery
Register for OTDC 2027 and connect with advances in Oligonucleotide Therapeutics, RNA Technologies, Drug Delivery, CRISPR & Aptamer Technologies.
📅 May 11–12, 2027 | Boston + Hybrid
🔗 oligo-nucleotide.com
#OTDC2027 #Oligonucleotides #RNATherapeutics #DrugDelivery
OTDC 2027 brings together emerging advances in Oligonucleotide Therapeutics, RNA Technologies, Drug Delivery, CRISPR & Aptamer Technologies.
📅 May 11–12, 2027
📍 Boston | Hybrid
🔗 oligo-nucleotide.com
#OTDC2027 #Oligonucleotides #RNATherapeutics
OTDC 2027 brings together emerging advances in Oligonucleotide Therapeutics, RNA Technologies, Drug Delivery, CRISPR & Aptamer Technologies.
📅 May 11–12, 2027
📍 Boston | Hybrid
🔗 oligo-nucleotide.com
#OTDC2027 #Oligonucleotides #RNATherapeutics
Standalone Software Tool for Annotating
Tandem Mass Spectra of Modified Ribonucleic Acids: AbstractRibonucleic
acid (RNA) modifications, with over 170 identified
types, play diverse roles in cellular processes. The past decade has
witnessed a surging demand for… #MassSpecRSS
Standalone Software Tool for Annotating
Tandem Mass Spectra of Modified Ribonucleic Acids: AbstractRibonucleic
acid (RNA) modifications, with over 170 identified
types, play diverse roles in cellular processes. The past decade has
witnessed a surging demand for… #MassSpecRSS
OTDC 2027 explores emerging advances in oligonucleotide therapeutics, RNA medicines, and innovative delivery technologies shaping the future of healthcare.
📅 May 11–12, 2027 | Boston, MA & Virtual
🔗 oligo-nucleotide.com
#OTDC2027 #RNA #DrugDelivery
OTDC 2027 explores emerging advances in oligonucleotide therapeutics, RNA medicines, and innovative delivery technologies shaping the future of healthcare.
📅 May 11–12, 2027 | Boston, MA & Virtual
🔗 oligo-nucleotide.com
#OTDC2027 #RNA #DrugDelivery
An investigational study of a novel individualised antisense oligonucleotide drug for CHCHD10-related #ALS shows early signs of efficacy in a 12-month N-of-1 study; Well tolerated, normalised plasma NfL levels & modest clinical improvements
www.cell.com/med/abstract...
An investigational study of a novel individualised antisense oligonucleotide drug for CHCHD10-related #ALS shows early signs of efficacy in a 12-month N-of-1 study; Well tolerated, normalised plasma NfL levels & modest clinical improvements
www.cell.com/med/abstract...